The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
BACKGROUND
Numerous prescription products have become available over the counter (OTC) in recent years. Previous simulation models have shown the Rx-to-OTC switch of loratadine to be cost effective.


OBJECTIVE
To empirically assess the overall effect of the Rx-to-OTC switch of loratadine and the specific effect of different pharmacy benefit structures on prescription drug utilization and cost among different plan sponsors.


METHODS
Data from a national pharmacy benefit management organization covering lives throughout the United States were used. The analysis included a comparison of the before and after change in prescription utilization and cost for plan sponsors that instituted 1 of 3 second-generation antihistamine (SGA) benefit responses: made no change, moved SGAs to the third tier, or restricted SGA benefits through a requirement for prior authorization. Multivariate regression analysis was used to control for differences across the study groups.


RESULTS
There was a substantial decrease in utilization and cost of all prescription drugs and combinations of drug classes. Patients with allergic rhinitis facing restricted prescription benefits for SGAs did not appear to increase utilization of other allergic rhinitis medications or other medications used to treat comorbid conditions such as asthma, sinusitis, and otitis media.


CONCLUSIONS
Utilization and cost decreased substantially for all types of medications and all pharmacy benefit structures. Future studies need to examine the effect of the Rx-to-OTC switch of loratadine and resultant prescription benefit policies on medical utilization and OTC antihistamine utilization.
Pharmaceutical Outcomes Research Program, University of Colorado School of Pharmacy, Department of Clinical Pharmacy, Denver 80262, USA. patrick.sullivan@uchsc.edu
Patrick W
PW
Sullivan
Kavita V
KV
Nair
Bimal V
BV
Patel
D000328:Adult; D000368:Aged; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002140:California; D003362:Cost-Benefit Analysis; D011307:Drug Prescriptions; D017723:Drug Utilization Review / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D017336:Loratadine / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D004366:Nonprescription Drugs; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy
D018926:Anti-Allergic Agents; D004366:Nonprescription Drugs; D017336:Loratadine